Solara Active Pharma Reports Strong Q2 FY27 Turnaround with Net Profit at ₹28.46 Crore
Solara Active Pharma Sciences Ltd · Outcome · 16 Oct 2026, 7:06 pm
Solara Active Pharma Reports Strong Q2 FY27 Turnaround with Net Profit at ₹28.46 Crore Solara Active Pharma Sciences reported consolidated revenue from operations of ₹417.34 crore for Q2 ended 30th Sep'26, up 33.1% YoY from ₹313.54 crore and 9.4% QoQ from ₹381.60 crore. Net profit stood at ₹28.46 crore, rebounding sharply from a net loss of ₹10.10 crore in Q2 ended 30th Sep'25 and up 74.5% QoQ from ₹16.31 crore, despite an exceptional loss of ₹4.50 crore on Vizag plant CWIP sale. Diluted EPS reached ₹5.92. Standalone Q2 revenue was ₹417.34 crore with net profit of ₹29.61 crore.
Original exchange filing (PDF)
More announcements from Solara Active Pharma Sciences Ltd
- Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026 · 23 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders .... · 18 Oct 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 · 17 Oct 2026
- Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026 · 17 Oct 2026
- Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026 · 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024 · 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA .... · 16 Oct 2026
- Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options. · 16 Oct 2026
